Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
- First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million
- VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026
- LIVMARLI oral tablet formulation FDA approved
- Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter 2025 and provided a business update.
'It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline,' said Chris Peetz, chief executive officer of Mirum. 'We're pleased with the FDA's approval of LIMARLI's tablet formulation, which provides more options for the ALGS and PFIC community in the U.S. in the form of a convenient single tablet dose. Our VISTAS study of volixibat in PSC is enrolling well and we expect to complete enrollment in the third quarter of this year. We're excited to continue our strong execution across our commercial medicines and pipeline throughout the year.'
Commercial: Raising full year revenue guidance to $435 to $450 million
First quarter 2025 global net product sales of $111.6 million.
First quarter 2025 LIVMARLI net product sales were $73.2 million representing 71% growth over first quarter 2024 net product sales.
Bile Acid Medicines net product sales were $38.4 million representing 47% growth over first quarter 2024 net product sales.
LIVMARLI oral tablet formulation approved.
LIVMARLI approved in Japan for ALGS and PFIC.
CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis.
Regulatory and Pipeline: Clinical milestones on track
Volixibat VISTAS study in primary sclerosing cholangitis (PSC) expected to complete enrollment in third quarter of 2025; topline data expected in the second quarter of 2026.
Oral presentation of 28-week interim data from volixibat in PBC (VANTAGE study) at EASL on Friday May 9th at 9:30am CEST.
Volixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in 2026.
LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026.
Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.
Corporate and Financial: Strong balance sheet and financial independence
Total revenue for the quarter ended March 31, 2025, was $111.6 million compared to $69.2 million for the quarter ended March 31, 2024.
Total operating expenses were $126.8 million for the quarter ended March 31, 2025 compared to $95.7 million for the quarter ended March 31, 2024.
Total operating expenses for the quarter ended March 31, 2025 included $21.9 million of non-cash stock-based compensation, intangible amortization, and other non-cash expenses compared to $17.1 million for the quarter ended March 31, 2024.
As of March 31, 2025, Mirum had unrestricted cash, cash equivalents and investments of $298.6 million compared to $292.8 million as of December 31, 2024.
Business Update Conference Call
Mirum will host a conference call today, May 7 th at 1:30 p.m. PT/4:30 p.m. ET, to provide business updates. Join the call using the following details:
Conference Call Details:
U.S./Toll-Free: +1 833 470 1428
International: +1 404 975 4839
Passcode: 549600
You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days.
About LIVMARLI® (maralixibat) oral solution and LIVMARLI® (maralixibat) tablets
LIVMARLI® (maralixibat) oral solution is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for two pediatric cholestatic liver diseases. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older. It is also approved in the U.S. for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older and in Europe for the treatment of PFIC in patients three months of age and older. For more information for U.S. residents, please visit LIVMARLI.com.
LIVMARLI has received orphan designation for ALGS and PFIC. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum's clinical trials section on the company's website.
IMPORTANT SAFETY INFORMATION
Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.
LIVMARLI can cause side effects, including
Liver injury. Changes in certain liver tests are common in patients with ALGS and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.
Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.
A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.
EU SmPC Canadian Product Monograph
About Volixibat
Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver. Volixibat is currently being evaluated in Phase 2b studies for primary sclerosing cholangitis (PSC) (VISTAS study), and primary biliary cholangitis (PBC) (VANTAGE study). In June, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and improvements in fatigue for patients treated with volixibat. No new safety signals were observed, and the most common adverse event was diarrhea with all cases mild to moderate. Volixibat has been granted breakthrough therapy designation for the treatment of PBC.
About CHOLBAM® (cholic acid) capsules
The FDA approved CHOLBAM (cholic acid) capsules in March 2015, the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder. The effectiveness of CHOLBAM has been demonstrated in clinical trials for bile acid synthesis disorders and the adjunctive treatment of peroxisomal disorders. An estimated 200 to 300 patients are current candidates for therapy.
CHOLBAM® (cholic acid) Indication
CHOLBAM is a bile acid indicated for
Treatment of bile acid synthesis disorders due to single enzyme defects.
Adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat-soluble vitamin absorption.
LIMITATIONS OF USE
The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders, including Zellweger spectrum disorders, have not been established.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS – Exacerbation of liver impairment
Monitor liver function and discontinue CHOLBAM in patients who develop worsening of liver function while on treatment.
Concurrent elevations of serum gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) may indicate CHOLBAM overdose.
Discontinue treatment with CHOLBAM at any time if there are clinical or laboratory indicators of worsening liver function or cholestasis.
ADVERSE REACTIONS
The most common adverse reactions (≥1%) are diarrhea, reflux esophagitis, malaise, jaundice, skin lesion, nausea, abdominal pain, intestinal polyp, urinary tract infection, and peripheral neuropathy.
Please see full Prescribing Information for additional Important Safety Information.
About CTEXLI™ (chenodiol) tablets
CTEXLI™ (chenodiol) tablets is FDA-approved for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Chenodiol is another name for chenodeoxycholic acid (CDCA). CDCA is a naturally occurring bile acid that was originally approved for the treatment of people with radiolucent stones in the gallbladder. CTEXLI was evaluated as part of the Phase 3 RESTORE study, the first and only clinical trial for CTX. CTX is a rare progressive disease that can affect the brain, spinal cord, tendons, eyes and arteries.
IMPORTANT SAFETY INFORMATION
CTEXLI can cause side effects, including:
Liver Injury: You will need to undergo laboratory testing before starting and while taking CTEXLI to check your liver function. Changes in certain liver tests may occur during treatment and may be a sign of liver injury. This can be serious. Stop taking CTEXLI immediately and tell your healthcare provider right away if you get any signs or symptoms of liver problems, including, stomach (abdomen) pain, bruising, dark-colored urine, feeling tired (fatigue), bleeding, yellowing of the skin and eyes, nausea, and itching.
Most Common Side Effects: Diarrhea, headache, stomach pain, constipation, high blood pressure, muscular weakness, and upper respiratory tract infection.
Tell your healthcare provider about all the medications that you take, as CTEXLI may interact with other medicines.
US Prescribing Information
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution and LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, significant increase or continued commercial results for our approved medicines, including continued financial growth, the potential achievement of our yearly financial guidance, continued strong execution across our approved medicines and pipeline, the results, enrollment, conduct and progress of our ongoing and planned studies for our product candidates, the timing and results of interim analyses of our ongoing studies and the regulatory approval path for our product candidates in any indication or any specific territory. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 'expected,' 'will,' 'could,' 'would,' 'guidance,' 'potential,' 'continue' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum's Annual Report for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Mirum Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheet Data
(in thousands)
(Unaudited)
March 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$
211,822
$
222,503
Short-term investments
65,852
57,812
Accounts receivable
95,852
78,286
Inventory
22,418
22,403
Prepaid expenses and other current assets
14,874
11,784
Total current assets
410,818
392,788
Restricted cash
425
425
Long-term investments
20,912
12,526
Intangible assets, net
243,845
249,819
Other noncurrent assets
14,245
15,196
Total assets
$
690,245
$
670,754
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$
11,639
$
14,618
Accrued expenses and other current liabilities
115,938
111,933
Total current liabilities
127,577
126,551
Operating lease liabilities, noncurrent
7,003
7,972
Convertible notes payable, net, noncurrent
308,509
308,082
Other liabilities
13,900
2,509
Total liabilities
456,989
445,114
Commitments and contingencies
Stockholders' equity:
Preferred stock
—
—
Common stock
5
5
Additional paid-in capital
892,367
870,189
Accumulated deficit
(658,858
)
(644,181
)
Accumulated other comprehensive loss
(258
)
(373
)
Total stockholders' equity
233,256
225,640
Total liabilities and stockholders' equity
$
690,245
$
670,754
Expand
Contacts
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Industry:
Biotechnology
Pharmaceutical
Health
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025...
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Will Stripe SPAC or IPO in 2025?
Key Points Webull, Chime, and Circle Internet Group are some popular fintech companies that went public during the past year. In addition, SoFi Technologies and Robinhood Markets have emerged as leading fintech stocks over incumbents such as Block or PayPal. Although Stripe is a highly coveted private company, investors are curious if the company will become the next hot fintech IPO. 10 stocks we like better than SoFi Technologies › During the past several years, a number of technology-driven companies have burst onto the scene in search of disrupting the financial services industry. Amid a flurry of public offerings from the likes of Webull, Chime, Circle Internet Group, Robinhood Markets, and SoFi Technologies (NASDAQ: SOFI), financial services unicorn Stripe has remained a private company. But with a reported valuation of $91.5 billion, Stripe exceeds the market capitalizations of incumbent fintech businesses such as PayPal and Block by a considerable margin. Let's dig into the paths that competing fintech companies took to public exchanges in recent years. From there, I'll outline some factors that may weigh on Stripe's decision to pursue a public offering in the near future. How do companies go public? During a traditional initial public offering (IPO) process, a company will engage a number of investment banking firms such as Goldman Sachs, Morgan Stanley, or JPMorgan Chase to assist with the underwriting process. Banks put together detailed documentation covering the company's historical financial profile, key performance indicators (KPIs), and risk factors around the business. This information is packaged in a regulatory filing known as an S-1 made with the Securities and Exchange Commission (SEC). From there, banks and executives conduct a roadshow during which they market and pitch the IPO offering to institutional investors and wealth management firms. This process helps gauge investor interest and how the offering should be priced. Another way to list on the public exchanges is through a special purpose acquisition company (SPAC). SPACs are colloquially referred to as "blank check companies" on Wall Street. Essentially, a sponsor will take a shell company public to raise capital. From there, the goal is to use those funds to merge with a private company and take it public . SPACs can be attractive for businesses as they typically offer a faster route to going public compared to traditional underwriting protocols led by investment banks. For investors, SPAC mergers may be more accessible than traditional IPO companies -- where allocations are generally first reserved for institutional investors. How have fintech offerings fared in recent years? Although SPACs may sound appealing as they can provide investors with access to popular start-ups in hot industries more easily than a traditional IPO, there are some important points to consider about these companies. According to a SPAC study conducted at the University of Florida, one-year de-SPAC (the transition period after a merger announcement) returns averaged negative 46.3% between 2012 and 2022. The average three-year return was even worse, posting a return of negative 57.7%. When it comes to industry-specific metrics, the median de-SPAC returns between 2009 and 2025 for crypto companies was negative 66% while broader financial services companies returned negative 6%. No matter which way you cut it, SPACs in the fintech realm have been largely underwhelming. By contrast, since Robinhood went public back in 2021 using the traditional IPO process, the shares have surged by 192% -- handily topping the 48% return from the S&P 500. Both Circle and Chime completed IPOs about a month ago and have posted mixed returns so far. While Circle stock went to the moon initially, it has since pulled back considerably (yet still trades much higher than its IPO price). Chime's action has been relatively muted, likely due to investors realizing that competing neobank SoFi is much larger and more profitable -- calling into question Chime's growth prospects. Should Stripe go public in 2025? Overall, I think the results have largely been mixed for public offerings in the fintech sector in recent years. I think a big reason for this performance is that despite impressive growth and differentiated product offerings, questions remain over how neobanks and new brokerage platforms can really compete and disrupt industry incumbents. In addition, I think Stripe is likely weighing how macro factors such as potential changes to Federal Reserve monetary policy could affect its own business results, sentiment across the broader capital markets, valuations, and appetites for public offerings. Whether Stripe should go public really hinges on the company's needs and whether it makes sense from a strategic and operational perspective. Should you buy stock in SoFi Technologies right now? Before you buy stock in SoFi Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoFi Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Adam Spatacco has positions in SoFi Technologies. The Motley Fool has positions in and recommends Block, Goldman Sachs Group, JPMorgan Chase, and PayPal. The Motley Fool recommends the following options: long January 2027 $42.50 calls on PayPal and short September 2025 $77.50 calls on PayPal. The Motley Fool has a disclosure policy. Will Stripe SPAC or IPO in 2025? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Here are 3 ways to think about Nvidia stock
Fortunes have been made by many, thanks to investing in chip giant Nvidia (NASDAQ: NVDA). Nvidia stock has soared 1,576% over the past five years. It is now the most valuable listed company in the world. I continue to weigh my options when it comes to investing. I would be happy to own Nvidia stock in my portfolio — but I am not willing to pay the current price. In making my decisions, I have been trying to think about the share from different perspectives. Here are three of them. Like Amazon before the dotcom crash Artificial intelligence (AI) has some signs of being a stock market bubble. If that bubble bursts, for example because computing power progress means future chip demand is much less than expected, it would likely have a big impact on Nvidia. That helps explain why I am nervous about buying at the current Nvidia stock price. If it falls down I would then be nursing a paper loss, perhaps a sizeable one. Then again, Amazon fell 94% between the dotcom boom of November 1999 and September 2001. Still, since then it has gone up 76,600%. As a long-term investor, I do not mind sitting on a paper loss (even a sizeable one) if I continue to believe in the long-term investment case for a share. But while Amazon in 1999 could be an interesting comparison for Nvidia stock today, there is no guarantee latter would bounce back the way the former did. Amazon's market grew significantly. The market for AI chips may keep growing fast – but it could also be that after initial installations are complete, demand falls. A bubble waiting to burst? That leads me onto another potential way to view Nvidia stock: as a massive bubble waiting to burst. After all, the price-to-earnings (P/E) ratio is 56. That is higher than I would be willing to pay, though large tech stocks often do command high P/E ratios. But earnings have exploded at Nvidia in recent years. Last year's basic earnings per share of $2.97 were far more than double the prior year's $1.21 – and around 25 times higher than just five years previously. If the surging demand for AI chips turns out to be a blip rather than a long-term trend, Nvidia's eanings could come crashing back to earth. In such a scenario, even if Nvidia remained solidly profitable, its stock price may move far below where it currently stands. This is the risk that most puts me off investing at the current share price. Success story set to grow A third scenario could be that Nvidia might be like Microsoft or Apple at multiple points in their history – massively successful yet set to grow further, boosting an already costly-looking share price. Apple stock is up 131% in the past five years. But five years ago, Apple was already massively successful and one of the biggest companies on the market. Nvidia's proprietary technology, large customer base and proven business model have brought it a long way in a few years. Maybe it can do the same again over the next few years. The post Here are 3 ways to think about Nvidia stock appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool C Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended Amazon, Apple, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
2 hours ago
- Yahoo
After Soaring Nearly 100% So Far This Year, Where Will Palantir Stock Be at the End of 2025?
Key Points Palantir has witnessed a meteoric rise in its share price thanks to the company's successful foray into the artificial intelligence (AI) arena. Several respected investors on Wall Street have been applying different approaches when it comes to investing in Palantir, making it hard to discern how "smart money" feels about the company. Palantir is trading for a historically high valuation, and broader buying and selling themes from institutional money managers could suggest a sell-off is on the horizon. 10 stocks we like better than Palantir Technologies › Outside of Nvidia, I'd argue that no other company has benefited from the tailwinds of the artificial intelligence (AI) revolution as much as data mining specialist Palantir Technologies (NASDAQ: PLTR). Over the last three years, shares of Palantir have gained more than 1,300%. Just this year alone, Palantir stock has rocketed by 97%. To put that into perspective, the S&P 500 and Nasdaq Composite indexes haven't even posted gains of 10% in 2025. While it can be tempting to follow the momentum in hopes of more outsize gains, smart investors understand that hope is not a real strategy. Let's explore the catalysts behind Palantir's generational run, and assess some recent trading activity to help discern whether Palantir stock could be headed even higher. The unprecedented rise in Palantir When AI first started to emerge as the next megatrend during late 2022 and early 2023, investors were consistently bombarded with news around big tech's splashy investments in the space. Microsoft plowed $10 billion into OpenAI, the maker of ChatGPT. Both Amazon and Alphabet invested hefty sums into a competing platform, called Anthropic. Tesla was touting its advancements in self-driving cars and humanoid robots. You get the drift -- the AI narrative largely hinged on the moves big tech was making. But in the background, Palantir was building. In April 2023, the company launched its fourth major software suite -- the Palantir Artificial Intelligence Platform (AIP). As the graph above illustrates, Palantir was a relatively slow-growth, cash-burning enterprise prior to the release of AIP. But since AIP's launch a little more than two years ago, Palantir's revenue has accelerated considerably. On top of that, the company has been able to command improving unit economics underscored by a sweeping transition to positive net income and generating billions in free cash flow. At the end of 2022, Palantir had 367 total customers. As of the end of the first quarter this year, Palantir boasted 769 total customers. Perhaps even more impressive is that the company's commercial customers (non-government) have risen by more than twofold over the last couple of years. To me, AIP is serving as a gateway for Palantir to expand its reach beyond federal contracts with the U.S. military, which is what Palantir is best known for. AIP represents a transformational shift as a defense contractor to a more ubiquitous software platform capable of penetrating the private sector, despite relentless competition from larger companies such as Salesforce or SAP. As a Palantir bull myself, I've been blown away by management's ability to outmaneuver big tech and deliver on lofty growth targets time and again. But as an investor, I can't help but wonder if the company's share price trajectory is sustainable. Is Wall Street trying to tell investors something? In addition to analyzing financial trends and operating metrics, investors can augment their due diligence process by listening to how Wall Street analysts talk about a company or even dig into the trading activity of notable investors. Thanks to a nifty tool called a form 13F, investors can access an itemized breakdown of all of the buys and sells from hedge funds during a given quarter. During the first quarter, famed billionaire investor Stanley Druckenmiller sold out of his fund's Palantir position. In addition, Cathie Wood has been trimming exposure to Palantir in Ark's portfolio as well. On the flip side, billionaire investors Ken Griffin and Israel Englander both added to their funds' respective Palantir positions during the first quarter. Given these dynamics, it might be hard to discern how Wall Street really feels about Palantir. I think there are some nuances to point out given the details above. First, both Druckenmiller and Wood have been in and out of Palantir stock in the past -- this is not the first time each investor reduced their exposure to the data analytics darling. On top of that, I think Griffin's and Englander's activity should be taken with a grain of salt. Both investors run highly sophisticated, multistrategy hedge funds. From time to time, some of this activity may include being a market maker. Although it may appear bullish that Palantir stock is held in Griffin's Citadel and Englander's Millennium Management portfolios, I wouldn't quite buy that narrative. Neither fund is necessarily known for holding positions for the long term. Moreover, as a multistrategy fund with a number of different teams and objectives, I think that it's highly likely that Citadel and Millennium have a layered and complex hedge strategy when it comes to owning a volatile growth stock such as Palantir. Where will Palantir stock be at the end of 2025? The chart below illustrates institutional buying and selling of Palantir stock over the last few years. Given that buying (the purple line) remains elevated over selling (the orange line), this could suggest that Palantir remains a favorite among institutional portfolios. However, as I expressed above, not all hedge funds and money managers have the same strategy. In other words, some of this elevated buying could be part of a broader, more complex trading strategy and less so an endorsement of long-term accumulation. Over the last few months, Palantir stock has become increasingly more expensive. In fact, the company is trading well beyond levels seen during peak days of the dot-com or COVID-19 bubbles. While it's impossible to know for certain where Palantir stock will be trading by the end of the year, smart investors know that nothing goes up in a straight line forever. A good indicator for how investors feel about Palantir's prospects should come after the company reports second-quarter earnings in a couple of weeks. As a reminder, shares fell off a cliff for a brief moment following the company's first-quarter blowout report. Expectations are rising with each passing report, and I would not be surprised to see Palantir stock sell off again -- even if its Q2 results are stellar. Given the convergence between institutional buying and selling, combined with Palantir's increasingly expensive valuation, I can't help but be cautious at this point. I do think a valuation correction could be in store sooner or later and would not be surprised if shares are trading for a considerably lower price by the end of the year. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Adam Spatacco has positions in Alphabet, Amazon, Microsoft, Nvidia, Palantir Technologies, and Tesla. The Motley Fool has positions in and recommends Alphabet, Amazon, Microsoft, Nvidia, Palantir Technologies, Salesforce, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. After Soaring Nearly 100% So Far This Year, Where Will Palantir Stock Be at the End of 2025? was originally published by The Motley Fool
